{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:21:15Z","timestamp":1791832875633,"version":"4.3.4"},"reference-count":54,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Adalimumab is a biological therapy used to treat different chronic inflammatory diseases. At present, there is an increasing number of adalimumab biosimilars. To assume the acceptability of interchangeability between reference adalimumab and biosimilars, there should be evidence about efficacy and safety of this switching. Regulation of this practice falls under the authority of individual European Union Member States. The aim of this study is to<\/jats:p><jats:p>systematically review the evidence on the efficacy, safety and immunogenicity of switching between reference adalimumab and biosimilars in different chronic immune\u2010mediated inflammatory diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Studies presenting data about switching between reference adalimumab and biosimilars were identified by sensitive search strategies in Medline and EMBASE from 1 January 2004 to 30 June 2021.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 471 references were obtained and 21 finally included in the analysis (total number of patients switching: 2802). Eight different adalimumab biosimilars were tested after receiving reference adalimumab. Eight articles included rheumatoid arthritis (RA), one miscellaneous rheumatic disease, six psoriasis (PSO) and six inflammatory bowel disease (IBD) patients. Overall, the efficacy results in the switching groups were comparable to those obtained in the arms of continuous biosimilar and continuous reference adalimumab. There were no significant differences in treatment emergent adverse events, anti\u2010drug or neutralising antibodies among the three groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Switching between reference adalimumab and biosimilars has no impact on efficacy, safety and immunogenicity in patients with RA, PSO and IBD. This finding was consistent for the different adalimumab biosimilars analysed. These conclusions could probably be extended to other rheumatic diseases such as psoriatic arthritis and ankylosing spondylitis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.15101","type":"journal-article","created":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T07:45:00Z","timestamp":1633765500000},"page":"1529-1550","source":"Crossref","is-referenced-by-count":48,"title":["Switching between reference adalimumab and biosimilars in chronic immune\u2010mediated inflammatory diseases: A systematic literature review"],"prefix":"10.1111","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1493-5937","authenticated-orcid":false,"given":"Nerea","family":"Garc\u00eda\u2010Beloso","sequence":"first","affiliation":[{"name":"Department of Pharmacy University Hospital Complex of Vigo  Vigo Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Altab\u00e1s\u2010Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Department of Rheumatology University Hospital Complex of Vigo  Vigo Spain"},{"name":"IRIDIS (Investigation in Rheumatology and Immune\u2010Mediated Diseases) Group Galicia Sur Health Research Institute, SERGAS\u2010UVIGO  Vigo Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol","family":"Samart\u00edn\u2010Ucha","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University Hospital Complex of Vigo  Vigo Spain"},{"name":"IRIDIS (Investigation in Rheumatology and Immune\u2010Mediated Diseases) Group Galicia Sur Health Research Institute, SERGAS\u2010UVIGO  Vigo Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Gayoso\u2010Rey","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University Hospital Complex of Vigo  Vigo Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Lu\u00edsa","family":"De Castro\u2010Parga","sequence":"additional","affiliation":[{"name":"Department of Digestive University Hospital Complex of Vigo  Vigo Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Salgado\u2010Barreira","sequence":"additional","affiliation":[{"name":"Methodology and Statistics Unit Galicia Sur Health Research Institute (IIS Galicia Sur, SERGAS\u2010UVIGO  Vigo Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Cibeira\u2010Badia","sequence":"additional","affiliation":[{"name":"Department of Scientific Library University Hospital Complex of Vigo  Vigo Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Guadalupe","family":"Pi\u00f1eiro\u2010Corrales","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University Hospital Complex of Vigo  Vigo Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gonz\u00e1lez\u2010Vilas","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital Complex of Vigo  Vigo Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Mar\u00eda","family":"Pego\u2010Reigosa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology University Hospital Complex of Vigo  Vigo Spain"},{"name":"IRIDIS (Investigation in Rheumatology and Immune\u2010Mediated Diseases) Group Galicia Sur Health Research Institute, SERGAS\u2010UVIGO  Vigo Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"Mart\u00ednez\u2010L\u00f3pez de Castro","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University Hospital Complex of Vigo  Vigo Spain"},{"name":"IRIDIS (Investigation in Rheumatology and Immune\u2010Mediated Diseases) Group Galicia Sur Health Research Institute, SERGAS\u2010UVIGO  Vigo Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,11,2]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"European Medicines Agency (EMA).Guidelines on similar biological medicinal products. Accessed December 7 2019.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/10\/WC500176768.pdf"},{"key":"e_1_2_10_3_1","unstructured":"US Food and Drug Administration.Guidance for Industry: Scientific considerations in demonstrating biosimilarity to a reference product. Rockville MD: US Food and Drug Administration; 2015. Accessed December 28 2020.https:\/\/www.fda.gov\/media\/82647\/download"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.5114\/reum.2018.77975"},{"key":"e_1_2_10_5_1","unstructured":"Biosimilars in the EU: information guide for health professionals.2019. Accessed October 24 2020.https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_en.pdf"},{"key":"e_1_2_10_6_1","unstructured":"Humira\u00ae (adalimumab).Information from the EMA. Accessed October 24 2020.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/humira"},{"key":"e_1_2_10_7_1","unstructured":"AbbVie.AbbVie reports full\u2010year and fourth\u2010quarter 2017 financial results 2018. Accessed April 2018.https:\/\/news.abbvie.com\/news\/abbvie-reports-full-year-and-fourth-quarter-2017-financial-results.htm"},{"key":"e_1_2_10_8_1","unstructured":"Halimatoz\u00ae (adalimumab biosimilar).EMA information. Accessed October 24 2020.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/halimatoz"},{"issue":"6","key":"e_1_2_10_9_1","first-page":"1118","article-title":"Adalimumab biosimilar in rheumatoid arthritis: a total\u2010evidence assessment to evaluate equivalence with the originator based on network meta\u2010analysis","volume":"36","author":"Mengato D","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4002-9"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-018-0769-6"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16890"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15857"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2018.05.009"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2018.01.024"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4186"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw138"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2019.09.012"},{"issue":"3","key":"e_1_2_10_19_1","first-page":"100","article-title":"Biosimilars of monoclonal antibodies in inflammatory diseases and cancer: current situation, challenges, and opportunities","volume":"44","author":"Calleja\u2010Hern\u00e1ndez M\u00c1","year":"2020","journal-title":"Farm Hosp"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40444"},{"issue":"6","key":"e_1_2_10_22_1","first-page":"914","article-title":"Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE\u2010RA equivalence study","volume":"77","author":"Cohen SB","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1857-3"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-2046-0"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13951"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-020-00447-6"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001578"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab460"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05199-w"},{"issue":"5","key":"e_1_2_10_30_1","article-title":"Single transition from adalimumab to ABP 501: evaluation of immunogenicity in a phase 3 study in subjects with moderate to severe plaque psoriasis","volume":"74","author":"Gooderham M","year":"2016","journal-title":"Journal of the American Academy of Dermatology"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18220"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.0221"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1923467"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa001"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89790-4"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab100"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15590"},{"issue":"2","key":"e_1_2_10_38_1","first-page":"155","article-title":"Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease: the extrapolation concept","volume":"113","author":"Ribaldone DG","year":"2021","journal-title":"Rev Esp Enferm Dig"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab027"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.2.14785"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1836"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.24.10.952"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01472-1"},{"key":"e_1_2_10_44_1","unstructured":"European Medicines Agency.Guideline on immunogenicity assessment of therapeutic proteins. Revision 1 2017. Accessed January 19 2021.https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14997"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.02.007"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000987"},{"key":"e_1_2_10_48_1","first-page":"1383","article-title":"Long\u2010term safety and efficacy of biosimilar infliximab (CT\u2010P13) after switching from originator infliximab: results from the 26\u2010week open label extension of a randomized Norwegian trial","volume":"69","author":"Goll GL","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216656"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216655"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.20344\/amp.8118"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002141"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw198"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208783"},{"key":"e_1_2_10_55_1","article-title":"Impact of switching on pharmacokinetics of therapeutic biologics and interchangeability assessment\u2014a simulation study","volume":"19","author":"Ji P","year":"2021","journal-title":"J Clin Pharmacol"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15101","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15101","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T23:20:29Z","timestamp":1693005629000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,2]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1111\/bcp.15101"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15101","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,2]]}}}